{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:36:02Z","timestamp":1792445762621,"version":"4.5.0"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Idiopathic inflammatory myopathies (IIMs), known also as myositis, represent challenging group of heterogeneous muscle disorders characterized by symmetric proximal muscle weakness and evidence of muscle inflammation. The purpose of this review is to provide important updates on cytokines and inflammatory mediators related to myositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the past 5 years, multiple studies brought a fresh insight into the pathogenesis of myositis by introducing new factors or further characterizing the role of the well established mediators in myositis. Among the mediators reviewed in this article, special attention was paid to interferons, C-X-C motif chemokine ligand 10, interleukin-18 and the IL23\/Th17 axis. Some of the recent work has also focused on the nontraditional cytokines, such as adipokines, myokines, S100 proteins, <jats:italic toggle=\"yes\">High Mobility Group Box 1<\/jats:italic> or B-cell activating factor and on several anti-inflammatory mediators. Moreover, microRNAs and their potential to reflect the disease activity or to regulate the inflammatory processes in myositis have recently been subject of intensive investigation. Some of the above-mentioned mediators have been proposed as promising clinical biomarkers or therapeutic targets for myositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Several recent studies contributed to a better understanding of the pathogenesis of myositis and highlighted the clinical significance of certain inflammatory mediators. Application of these new findings may help to develop innovative approaches for patients\u2019 phenotyping, disease activity monitoring and potentially novel therapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000744","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:23:51Z","timestamp":1600280631000},"page":"534-541","source":"Crossref","is-referenced-by-count":22,"title":["Cytokines and inflammatory mediators as promising markers of polymyositis\/dermatomyositis"],"prefix":"10.1097","volume":"32","author":[{"given":"Lucie Andr\u00e9s","family":"Cerezo","sequence":"first","affiliation":[{"name":"Institute of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Vencovsk\u00fd","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology"},{"name":"Department of Rheumatology, 1Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"\u0160enolt","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology"},{"name":"Department of Rheumatology, 1Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.rdc.2019.07.006","article-title":"Idiopathic inflammatory myopathies","volume":"45","author":"Vencovsk\u00fd","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0000000000000435","article-title":"MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies","volume":"29","author":"Kub\u00ednov\u00e1","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/BOR.0000000000000548","article-title":"New insights in myositis-specific autoantibodies","volume":"30","author":"Ghirardello","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/BOR.0b013e3283317b31","article-title":"Role of cytokines and chemokines in idiopathic inflammatory myopathies","volume":"21","author":"De Paepe","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"e000811","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2011.05.055","article-title":"Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-\u03b3 signaling cascade in attacked versus nonattacked myofibers","volume":"179","author":"Ivanidze","year":"2011","journal-title":"Am J Pathol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-5728(03)00218-2","article-title":"Expression of IFN-gamma-inducible chemokines in inclusion body myositis","volume":"141","author":"Raju","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00401-005-0989-5","article-title":"Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies","volume":"109","author":"De Paepe","year":"2005","journal-title":"Acta Neuropathol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"e88788","DOI":"10.1371\/journal.pone.0088788","article-title":"Th1 response and systemic Treg deficiency in inclusion body myositis","volume":"9","author":"Allenbach","year":"2014","journal-title":"PLoS One"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar4583","article-title":"Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse","volume":"16","author":"Kim","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjd.17079","article-title":"Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis","volume":"179","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fimmu.2018.00763","article-title":"Unique action of interleukin-18 on T cells and other immune cells","volume":"9","author":"Nakanishi","year":"2018","journal-title":"Front Immunol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.2006.03180.x","article-title":"Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies","volume":"146","author":"Tucci","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cyto.2012.07.011","article-title":"Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases","volume":"60","author":"Shen","year":"2012","journal-title":"Cytokine"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/keq196","article-title":"Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5606\/ArchRheumatol.2017.6175","article-title":"Serum interleukin-18 level is associated with disease activity and interstitial lung disease in patients with dermatomyositis","volume":"32","author":"Yang","year":"2017","journal-title":"Arch Rheumatol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10067-015-3080-1","article-title":"Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease","volume":"35","author":"Zou","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/rheumatology\/key222","article-title":"Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment","volume":"57","author":"Helmers","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cei.12445","article-title":"Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications","volume":"178","author":"Moran","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/art.11428","article-title":"Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells","volume":"50","author":"Page","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/cei.12311","article-title":"Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis","volume":"177","author":"Fujiyama","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000452563","article-title":"MiR-146a regulates inflammatory infiltration by macrophages in polymyositis\/dermatomyositis by targeting TRAF6 and affecting IL-17\/ICAM-1 pathway","volume":"40","author":"Yin","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/03009742.2014.956141","article-title":"Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies","volume":"44","author":"Notarnicola","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2010.517215","article-title":"Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis","volume":"40","author":"Shen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10067-018-4046-x","article-title":"Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults","volume":"37","author":"Gupta","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R34-20230829","first-page":"656","article-title":"Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis","volume":"37","author":"Silva","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1089\/jir.2012.0030","article-title":"IL-17\/IFN-\u03b3 interactions regulate intestinal inflammation in TNBS-induced acute colitis","volume":"32","author":"Jin","year":"2012","journal-title":"J Interferon Cytokine Res"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"e60900","DOI":"10.1371\/journal.pone.0060900","article-title":"Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2, 3-deoxygenase","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.4103\/0366-6999.213419","article-title":"Upregulation of interleukin 21 and interleukin 21 receptor in patients with dermatomyositis and polymyositis","volume":"130","author":"Liu","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4049\/immunohorizons.1700053","article-title":"IL-21 exacerbates autoimmune myositis by enhancing the accumulation of GM-CSF-producing \u03b3\u03b4 T cells in the muscle","volume":"1","author":"Kageyama","year":"2017","journal-title":"ImmunoHorizons"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/rheumatology\/key341","article-title":"CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease (published correction appears in Rheumatology (Oxford)","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/art.33350","article-title":"Immature muscle precursors are a source of interferon-\u03b2 in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation","volume":"64","author":"Tournadre","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1038\/s41598-018-23539-4","article-title":"Interleukin-23 as a therapeutic target for inflammatory myopathy","volume":"8","author":"Umezawa","year":"2018","journal-title":"Sci Rep"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9440(10)63454-2","article-title":"Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases","volume":"163","author":"Seeliger","year":"2003","journal-title":"Am J Pathol"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar4311","article-title":"Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis","volume":"15","author":"Nistala","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s13075-014-0468-2","article-title":"The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies","volume":"16","author":"Ple\u0161tilov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2018.12.023","article-title":"Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis","volume":"116","author":"Andr\u00e9s Cerezo","year":"2019","journal-title":"Cytokine"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar3836","article-title":"Resistin in idiopathic inflammatory myopathies","volume":"14","author":"Filkov\u00e1","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12950-015-0075-2","article-title":"Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures","volume":"12","author":"Olazagasti","year":"2015","journal-title":"J Inflamm (Lond)"},{"key":"R48-20230829","first-page":"222","article-title":"Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients","volume":"34","author":"Hulejov\u00e1","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","article-title":"The expression of BAFF in the muscles of patients with dermatomyositis","volume":"249","author":"Baek","year":"2012","journal-title":"J Neuroimmunol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Krystufkov\u00e1","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"16","author":"Kry\u0161t\u016ffkov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1189\/jlb.72.2.410","article-title":"Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1","volume":"72","author":"Xu","year":"2002","journal-title":"J Leukoc Biol"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00296-017-3752-z","article-title":"Serum levels of adipokines in patients with idiopathic inflammatory myopathies: a pilot study","volume":"37","author":"Loaiza-F\u00e9lix","year":"2017","journal-title":"Rheumatol Int"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/BOR.0000000000000337","article-title":"The role of myokines in muscle health and disease","volume":"28","author":"Lightfoot","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"154966","DOI":"10.1016\/j.cyto.2019.154966","article-title":"The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis","volume":"127","author":"De Paepe","year":"2020","journal-title":"Cytokine"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1093\/rheumatology\/kez651","article-title":"Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies","volume":"59","author":"Vernerov\u00e1","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/annrheumdis-2011-200495","article-title":"Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor \u03b1 expression in muscle tissue of patients with polymyositis or dermatomyositis","volume":"71","author":"Zong","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.4049\/jimmunol.164.12.6593","article-title":"Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production","volume":"164","author":"Sugiura","year":"2000","journal-title":"J Immunol"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/intimm\/dxf062","article-title":"Increased IL-15 production of muscle cells in polymyositis and dermatomyositis","volume":"14","author":"Sugiura","year":"2002","journal-title":"Int Immunol"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"43230","DOI":"10.18632\/oncotarget.6462","article-title":"The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies","volume":"6","author":"Ruck","year":"2015","journal-title":"Oncotarget"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.gene.2016.06.055","article-title":"IL-15 up-regulates the MMP-9 expression levels and induces inflammatory infiltration of macrophages in polymyositis through regulating the NF-kB pathway","volume":"591","author":"Yan","year":"2016","journal-title":"Gene"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1038\/s41598-017-13479-w","article-title":"IL-15 promotes human myogenesis and mitigates the detrimental effects of TNF\u03b1 on myotube development","volume":"7","author":"O\u2019Leary","year":"2017","journal-title":"Sci Rep"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.20220","article-title":"Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids","volume":"50","author":"Ulfgren","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.expneurol.2015.05.023","article-title":"HMGB1 and RAGE in skeletal muscle inflammation: implications for protein accumulation in inclusion body myositis","volume":"271","author":"Muth","year":"2015","journal-title":"Exp Neurol"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1096\/fj.09-144782","article-title":"Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies","volume":"24","author":"Grundtman","year":"2010","journal-title":"FASEB J"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/annrheumdis-2012-202207","article-title":"TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis","volume":"72","author":"Zong","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"e0161436","DOI":"10.1371\/journal.pone.0161436","article-title":"HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis\/dermatomyositis with interstitial lung disease","volume":"11","author":"Shu","year":"2016","journal-title":"PLoS One"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fcell.2020.00226","article-title":"Aberrant expression of high mobility group box protein 1 in the idiopathic inflammatory myopathies","volume":"8","author":"Day","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/bmm.13.124","article-title":"B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis","volume":"8","author":"Peng","year":"2014","journal-title":"Biomark Med"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3899\/jrheum.140977","article-title":"Increased serum B-cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis","volume":"42","author":"Kobayashi","year":"2015","journal-title":"J Rheumatol"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/mus.25405","article-title":"Transforming growth factor-\u03b2 signaling is upregulated in sporadic inclusion body myositis","volume":"55","author":"Noda","year":"2017","journal-title":"Muscle Nerve"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40001-019-0368-7","article-title":"Detection of serum MCP-1 and TGF-\u03b21 in polymyositis\/dermatomyositis patients and its significance","volume":"24","author":"Wu","year":"2019","journal-title":"Eur J Med Res"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"657","DOI":"10.21873\/invivo.11108","article-title":"Elevated IL-4 and IFN-\u03b3 levels in muscle tissue of patients with dermatomyositis","volume":"31","author":"Giri\u015f","year":"2017","journal-title":"In Vivo (Brooklyn)"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.autrev.2015.08.006","article-title":"Insights into IL-37, the role in autoimmune diseases","volume":"14","author":"Xu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R75-20230829","doi-asserted-by":"crossref","first-page":"9187","DOI":"10.12659\/MSM.910904","article-title":"Interleukin-37 (IL-37) suppresses pertussis toxin-induced inflammatory myopathy in a rat model","volume":"24","author":"Yan","year":"2018","journal-title":"Med Sci Monit"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/BOR.0000000000000225","article-title":"The role of microRNAs in the idiopathic inflammatory myopathies","volume":"27","author":"Parkes","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"R77-20230829","first-page":"161","article-title":"Serum miR-21 levels in patients with dermatomyositis","volume":"31","author":"Shimada","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"R78-20230829","first-page":"764","article-title":"hsa-miR-7 is a potential biomarker for idiopathic inflammatory myopathies with interstitial lung disease in humans","volume":"48","author":"Yu","year":"2018","journal-title":"Ann Clin Lab Sci"},{"key":"R79-20230829","first-page":"17","article-title":"Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activity","volume":"34","author":"Misunova","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R80-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-017-0058-1","article-title":"Circulating plasma microRNA profiling in patients with polymyositis\/dermatomyositis before and after treatment: miRNA may be associated with polymyositis\/dermatomyositis","volume":"38","author":"Hirai","year":"2018","journal-title":"Inflamm Regen"},{"key":"R81-20230829","doi-asserted-by":"crossref","first-page":"2927061","DOI":"10.1155\/2019\/2927061","article-title":"Specific autoantibodies and clinical phenotypes correlate with the aberrant expression of immune-related microRNAs in dermatomyositis","volume":"2019","author":"Ye","year":"2019","journal-title":"J Immunol Res"},{"key":"R82-20230829","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/art.38292","article-title":"Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies","volume":"66","author":"Georgantas","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R83-20230829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3899\/jrheum.141474","article-title":"MicroRNA-10a regulation of proinflammatory mediators: an important component of untreated juvenile dermatomyositis","volume":"43","author":"Xu","year":"2016","journal-title":"J Rheumatol"},{"key":"R84-20230829","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s12035-016-9769-6","article-title":"Estrogen downregulates miR-21 expression and induces inflammatory infiltration of macrophages in polymyositis: role of CXCL10","volume":"54","author":"Yan","year":"2017","journal-title":"Mol Neurobiol"},{"key":"R85-20230829","first-page":"1332","article-title":"MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1","volume":"53","author":"Liu","year":"2018","journal-title":"Int J Oncol"},{"key":"R86-20230829","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fimmu.2020.00037","article-title":"Reduced miR-146a promotes REG3A expression and macrophage migration in polymyositis and dermatomyositis","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"R87-20230829","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/art.41215","article-title":"Muscle weakness in myositis: microRNA-mediated dystrophin reduction in a myositis mouse model and human muscle biopsies","volume":"72","author":"Kinder","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:14:26Z","timestamp":1693293266000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000744","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}